newsfilter
← Latest News
GlobeNewswire·

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease Clear and near-term value inflection points, with blinded 6-month interim data